Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed at expanding its late-stage clinical development program of the mineralocorticoid receptor antagonist (MRA) Kerendia (finerenone) for heart failure (HF). These new trials will broaden the patient pool to include those with reduced (HfrEF), mildly reduced (HfmrEF), and preserved ejection fraction (HfpEF), building upon the current study which focuses on HfmrEF and HfpEF.
Significant Expansion of Clinical Trials
The new trials are expected to significantly expand the participant base, with the company aiming to reach a total of 15,000 volunteers, making it one of the largest HF trials ever conducted. This substantial commitment to clinical research underscores Bayer’s dedication to advancing treatments for heart failure and improving patient outcomes across the spectrum of HF types.
Implications for Heart Failure Treatment
The addition of these trials to the existing program will provide valuable data on the efficacy and safety of Kerendia in a diverse range of heart failure patients. This could potentially lead to new treatment options for patients with different presentations of the disease, enhancing the standard of care in the management of heart failure.-Fineline Info & Tech
